KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis.

Parameswaran K Nair, Bernhard Hellmich, Arnaud Bourdin, David R W Jayne, Florence Roufosse, Nader Khalidi, Lena Börjesson Sjö, Ying Fan, Christopher McCrae, Sofia Necander, Eva Rodríguez-Suárez, Anat Shavit, Claire Walton, Peter A Merkel, Michael E Wechsler

Arthritis Rheumatol 78(3) 695-704

PMID40977418
PMCIDPMC12991915
DOI10.1002/art.43398
发表日期2025-09-22
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。
摘要

摘要

OBJECTIVE: The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab-treated patients achieved complete withdrawal of oral glucocorticoids (OGCs). The objectives of this post hoc analyses are to further elucidate the efficacy of benralizumab and mepolizumab in facilitating reductions in OGCs through investigating timings and sustainability of reducing OGCs as well as the cumulative use of OGCs. METHODS: Adults with EGPA requiring ≥7.5 mg/day OGC with or without immunosuppressive therapy were randomized to benralizumab 30 mg (n = 70) or mepolizumab 300 mg (n = 70) subcutaneously every 4 weeks for 52 weeks. Investigators tapered OGCs for patients with stable EGPA based on clinical judgment. Reductions in OGC use (to ≤4 mg/day, by ≥50%, or complete withdrawal) were considered sustained if achieved by week 40 and maintained through week 52. RESULTS: The 12-month cumulative dose of OGC was approximately 1,800 mg in both groups. At weeks 49 to 52, the median OGC dose was 1.16 (minimum-maximum 0.0-16.6) and 3.00 (minimum-maximum 0.0-25.7) mg/day for benralizumab and mepolizumab, respectively. Time to first or sustained OGC reduction to ≤4 mg/day or by ≥50% and accrued OGC-free duration were similar between groups. More benralizumab- than mepolizumab-treated patients completely withdrew OGCs (33 of 70 vs 20 of 70; hazard ratio [HR] for the time to the first complete withdrawal 1.84 [95% confidence interval [CI] 1.06-3.27]; unstratified log-rank test P = 0.0291) and sustained complete withdrawal (17 of 70 vs 7 of 70; HR for time to reduction 2.97 [95% CI 1.26-7.77]; unstratified log-rank test P = 0.0268). In both groups, complete OGC withdrawal was similar across patient subgroups, including by antineutrophilic cytoplasmic antibody status and immunosuppressive use. CONCLUSION: Targeting the interleukin-5 receptor with benralizumab or circulating interleukin-5 with mepolizumab are effective OGC-sparing strategies in patients with EGPA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Time to first (A) OGC reduction to ≤4 mg/day, (B) ≥50% OGC reduction, and (C) complete OGC withdrawal. Time to first reduction was defined as the date of randomization to the first 4‐week period meeting the OGC reduction threshold. The HR (benralizumab vs mepolizumab) and 95% CI were estimated using a Cox regression model with the Efron method to control for ties. The covariates in the model included treatment arm, baseline dose of prednisone, baseline Birmingham Vasculitis Activity Score, and region. An HR of >1 favored benralizumab. P values were derived from an unstratified log‐rank test. CI, confidence interval; HR, hazard ratio; OGC, oral glucocorticoid.
非 KM Figure
Figure 2Time to sustained (A) OGC reduction to ≤4 mg/day, (B) ≥50% OGC reduction, and (C) complete OGC withdrawal. Time to sustained reduction was defined as achieving OGC ≤4 mg/day, ≥50% OGC reduction, or complete OGC withdrawal by week 40 and maintaining reduction through to week 52. The HR (benralizumab vs mepolizumab) and 95% CI were estimated using a Cox regression model with the Efron method to control for ties. The covariates in the model included treatment arm, baseline dose of prednisone, baseline Birmingham Vasculitis Activity Score, and region. An HR of >1 favored benralizumab. P values were derived from an unstratified log‐rank test. CI, confidence interval; HR, hazard ratio; OGC, oral glucocorticoid.
非 KM Figure
Figure 3Heatmap of the average daily dose of OGCs throughout the double‐blind period. Each row represents a single patient's OGC use over time during the study. Decreasing OGC doses are represented by a gradient from red to orange and yellow to green, with dark green and “0” denoting 0 mg/day OGC. OGC, oral glucocorticoid; R, relapse.
非 KM Figure
Figure 4A subgroup analysis of the proportion of patients achieving complete OGC withdrawal during weeks 48 through 52. Rates and the difference (benralizumab − mepolizumab) were estimated using the marginal standardization method in a logistic regression model. The covariates in the model included treatment arm, subgroup, and interaction between treatment arm and the subgroup (treatment arm × subgroup). The P value for each interaction term was estimated from logistic regression without using the marginal standardization method. ANCA, antineutrophilic cytoplasmic antibody; CI, confidence interval; EGPA, eosinophilic granulomatosis with polyangiitis; NA, not applicable; OGC, oral glucocorticoid; VDI, Vasculitis Damage Index.
非 KM Figure